(Q35639095)

9 August 2017

title

Potential pitfalls of crossover and thoughts on iniparib in triple-negative breast cancer (English)

1 reference

9 August 2017

3

Susan E Bates

1 reference

9 August 2017

1

Tito Fojo

1 reference

9 August 2017

author name string

Laleh Amiri-Kordestani

series ordinal

2

1 reference

9 August 2017

language of work or name

English

0 references

publication date

1 November 2011

1 reference

Journal of the National Cancer Institute

9 August 2017

published in

1 reference

9 August 2017

volume

103

1 reference

9 August 2017

issue

23

1 reference

9 August 2017

page(s)

1738-1740

1 reference

Iniparib plus chemotherapy in metastatic triple-negative breast cancer

9 August 2017

cites work

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3247787

Combination treatment with MEK and AKT inhibitors is more effective than each drug alone in human non-small cell lung cancer in vitro and in vivo

27 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3247787

A Phase II, Open-Label, Randomized Study to Assess the Efficacy and Safety of AZD6244 (ARRY-142886) Versus Pemetrexed in Patients with Non-small Cell Lung Cancer Who Have Failed One or Two Prior Chemotherapeutic Regimens

27 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3247787

A phase II study of PD-0325901, an oral MEK inhibitor, in previously treated patients with advanced non-small cell lung cancer

27 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3247787

Progression-free survival is simply a measure of a drug's effect while administered and is not a surrogate for overall survival.

27 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3247787

Overall survival and updated results for sunitinib compared with interferon alfa in patients with metastatic renal cell carcinoma

27 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3247787

Effective sensitization of temozolomide by ABT-888 is lost with development of temozolomide resistance in glioblastoma xenograft lines

27 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3247787

Sunitinib versus interferon alfa in metastatic renal-cell carcinoma

27 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3247787

Multicenter phase II study of the oral MEK inhibitor, CI-1040, in patients with advanced non-small-cell lung, breast, colon, and pancreatic cancer

27 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3247787

High dose cisplatin and high dose carboplatin in refractory ovarian cancer.

27 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3247787

High-dose carboplatin in refractory ovarian cancer patients.

27 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3247787

High-dose cisplatin in hypertonic saline in refractory ovarian cancer

27 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3247787

Oncologists' reluctance to accrue patients onto clinical trials: an Illinois Cancer Center study

27 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3247787

Cancer trial enrollment after state-mandated reimbursement

27 July 2018

1 reference

Crossref

https://api.crossref.org/works/10.1093%2FJNCI%2FDJR386

Phase III study of immediate compared with delayed docetaxel after front-line therapy with gemcitabine plus carboplatin in advanced non-small-cell lung cancer

21 January 2018

1 reference

Crossref

https://api.crossref.org/works/10.1093%2FJNCI%2FDJR386

Phase I and pharmacodynamic study of the oral MEK inhibitor CI-1040 in patients with advanced malignancies

21 January 2018

1 reference

Crossref

https://api.crossref.org/works/10.1093%2FJNCI%2FDJR386

Palliative chemotherapy during the last month of life

21 January 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3247787

How sociodemographics, presence of oncology specialists, and hospital cancer programs affect accrual to cancer treatment trials

25 September 2018

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/22045362

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Dose intensity analysis of chemotherapy regimens in ovarian carcinoma

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/22045362

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

A Phase II, open-label, randomised study to assess the efficacy and safety of the MEK1/2 inhibitor AZD6244 (ARRY-142886) versus capecitabine monotherapy in patients with colorectal cancer who have failed one or two prior chemotherapeutic regimens

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/22045362

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Identifiers

DOI

10.1093/JNCI/DJR386

1 reference

9 August 2017

1 reference

9 August 2017

1 reference